spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Ranexa 

 HSMN NewsFeed - 5 Nov 2018
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2018
New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
Devices Surgery Product Launch
 HSMN NewsFeed - 26 Jul 2016
AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR(TM) (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 Mar 2013
Labrys Biologics Announces Key Executive Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2012
APP Pharmaceuticals Acquires Three Products from Nexus
Biopharmaceuticals Generics Acquisitions
 HSMN NewsFeed - 10 May 2010
Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 23 Nov 2009
Four Senior Executives Join Orexigen(R) Therapeutics Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Jun 2009
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 2 Apr 2009
Xanodyne's New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Mar 2009
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Feb 2009
Astellas Commences Tender Offer to Acquire All Outstanding Shares of CV Therapeutics for $16.00 Per Share in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Jan 2009
CV Therapeutics Statement on Unsolicited Proposal From Astellas
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 27 Jan 2009
Astellas Proposes to Acquire CV Therapeutics for $16 per Share in Cash
Biopharmaceuticals Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 14 Aug 2008
CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 5 Aug 2008
Xanodyne Achieves Positive Efficacy Results in Pivotal Phase 3 Studies of Proprietary Modified Release Oral Tranexamic Acid Product Candidate for Heavy Menstrual Bleeding
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2008
European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 15 Apr 2008
CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Biopharmaceuticals
 HSMN NewsFeed - 1 Apr 2008
CV Therapeutics' Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 4 Feb 2008
CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology
Devices Licensing
 HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 18 Dec 2007
FDA Approves New Mechanism of Action Labeling for Ranexa(R)
Biopharmaceuticals. Cardiology FDA
 HSMN NewsFeed - 7 Dec 2007
FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Dec 2007
Depomed Names Michael Sweeney Vice President of Product Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Nov 2007
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Nov 2007
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 5 Nov 2007
Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 Nov 2007
Bayer Temporarily Suspends Global Trasylol(R) Marketing
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2007
CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 15 Aug 2007
Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Aug 2007
CV Therapeutics Launches 1000 mg Ranexa(R) Tablet
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 30 Jul 2007
OMRIX Biopharmaceuticals Submits Market Authorization Application (MAA) to European Medicines Agency (EMEA) for Approval to Market Evicel(TM) with General Hemostasis Indication
Biopharmaceuticals Surgery Regulatory
 HSMN NewsFeed - 16 Jul 2007
CV Therapeutics Names Lewis Stuart Senior Vice President, Commercial Operations
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 31 May 2007
Peter M. Strumph Named CEO of Nile Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2007
CV Therapeutics Significantly Reduces Operating Expenses
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2007
CV Therapeutics Submits New Drug Application For Regadenoson
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 24 Apr 2007
Journal of the American Medical Association Publishes MERLIN TIMI-36 Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Mar 2007
JACC Publishes Long-Term Safety and Tolerability Data from Ranolazine Open Label Experience (ROLE) Program
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Mar 2007
CV Therapeutics Announces Topline MERLIN TIMI-36 Results
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Dec 2006
CV Therapeutics Files Application for European Marketing Approval of Ranolazine for Treatment of Chronic Angina
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 4 Dec 2006
Regadenoson Meets Primary Endpoint in Second Phase 3 Clinical Trial
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Oct 2006
CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2006
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 11 Oct 2006
CV Therapeutics Ending Co-Promotion of ACEON(R) (perindopril erbumine) Tablets
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2006
CV Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office and European Patent Office for Drug-Eluting Stent Technology
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Sep 2006
Bayer Acknowledges That New Trasylol Study Was Not Disclosed Prior to Recent FDA Cardio-Renal Advisory Committee Meeting
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 26 Sep 2006
CV Therapeutics Completes MERLIN TIMI-36 Study
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 Sep 2006
Kos Announces Positive Overall Results for Two Phase III Trials of Icatibant for the Treatment of Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 7 Jul 2006
CV Therapeutics Announces MERLIN TIMI-36 Study to Continue as Planned Based on Final Scheduled DSMB Meeting
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 22 Jun 2006
CV Therapeutics Acquires Rights to Ranolazine in Asia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 May 2006
Angina Patients Cost Managed Care Over Twice as Much as Coronary Artery Disease Patients Without Angina
Biopharmaceuticals Cardiology
Return to NewsFeed  

 Additional items found! 25

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 25 additional stories matching:
Ranexa
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.